{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002065","form_type":"8-K","ticker":"RMTI","cik":"0001041024","company_name":"ROCKWELL MEDICAL, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.195554+00:00","generated_at":"2026-06-07T01:55:40.331281+00:00","sec_items":["1.01","2.02","8.01","2.03","3.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rockwell Medical extends loan maturity to 2029, provides preliminary Q4 net sales $21.3M-$22.3M","bullets":["Amended loan with Innovatus: $8.0M principal, interest-only 30-36 months, maturity extended from Mar 2025 to Jan 2029.","Issued warrant to Innovatus for 191,096 shares at $1.83 per share, exercisable through Jan 2029.","Preliminary Q4 2023 net sales $21.3M-$22.3M (10-16% YoY growth); gross profit $1.6M-$2.6M; adj. EBITDA ($0.9M)-$0.1M.","Full-year 2023 net sales projected $82.8M-$83.8M (14-15% growth); gross profit $7.4M-$8.4M; adj. EBITDA ($5.5M)-($4.5M).","Cash and equivalents $11.0M at Dec 31, 2023, down slightly from $11.7M at Sep 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002065","json":"https://secwatch.observer/filing/0001104659-24-002065.json","markdown":"https://secwatch.observer/filing/0001104659-24-002065.md","text":"https://secwatch.observer/filing/0001104659-24-002065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/0001104659-24-002065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/tm242195d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:55:40.331281+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9de65a1b9069b8c3c1c09cc4237992c62473d43b","claim":"ROCKWELL MEDICAL, INC. amended credit facility of $8.0 million with Innovatus Life Sciences Lending Fund I, LP at the greater of (i) Prime Rate and (ii) 7.50%, plus 3.50% maturing fifth anniversary of the Effective Date.","evidence_excerpt":"for the continuation of term loans initially borrowed on or after the Original Effective Date, in an aggregate outstanding principal amount as of the Effective Date of $8.0 million (the “Term Loans”). The Company will make interest-only payments on the Term Loans for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/0001104659-24-002065-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$8.0 million"},{"label":"Counterparty","value":"Innovatus Life Sciences Lending Fund I, LP"},{"label":"Rate","value":"the greater of (i) Prime Rate and (ii) 7.50%, plus 3.50%"},{"label":"Maturity","value":"fifth anniversary of the Effective Date"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"35f130a51d540658b47e358e6a018dbf1bedd364","claim":"ROCKWELL MEDICAL, INC. reported three months ended December 31, 2023 results: revenue between $21.3 million and $22.3 million, net income ($2.2) to ($1.2). Guidance reaffirmed.","evidence_excerpt":"8, 2024. 1 Rockwell Medical Preliminary Fourth Quarter and Full-Year 2023 Projected Results Rockwell Medical projects net sales in the fourth quarter of 2023 to be between $21.3 million and $22.3 million, a 10% to 16% increase over net sales of $19.3 million for the same period in 2022; gross profit for the fourth quarter of 2023 to be between $1.6 million and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/0001104659-24-002065-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2023"},{"label":"Revenue","value":"between $21.3 million and $22.3 million"},{"label":"Net income","value":"($2.2) to ($1.2)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"57bbe08f806d74e5b6169838705ff14155c0742f","claim":"ROCKWELL MEDICAL, INC. reported twelve months ended December 31, 2023 results: revenue between $82.8 million and $83.8 million, net income ($9.1) to ($8.1). Guidance reaffirmed.","evidence_excerpt":"in the fourth quarter of 2023. Rockwell Medical is narrowing its full-year 2023 guidance and projects net sales for the twelve months ended December 31, 2023 to be between $82.8 million and $83.8 million, a 14% to 15% increase over net sales of $72.8 million in 2022, and gross profit for the full-year 2023 to be between $7.4 million and $8.4 million, an 80% to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/0001104659-24-002065-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"twelve months ended December 31, 2023"},{"label":"Revenue","value":"between $82.8 million and $83.8 million"},{"label":"Net income","value":"($9.1) to ($8.1)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}